Abstract: Fifteen novel glycyrrhetinic acid derivatives containing a nitrogen heterocycle at C-30 and with different A-ring substituents were designed and synthesized. All of these derivatives have improved antiproliferative effects against human HL-60 leukemia cells. Compounds with a cyano-enone functionality on the A-ring exhibit greater growth inhibitory effects, compared to those with a 2-hydroxymethylene-3-keto, an isoxazole, or a 2-cyano-3-keto group. N- (2-cyano-3,11-dioxoolean-1,12-dien-30-yl)-4-piperidyl piperidine (9b) was found to be two-fold more potent than methyl 2-cyano-3,11-dioxooleana-1,12-dien-30-oate (CDODO-Me-11).
Introduction
18β-Glycyrrhetinic acid (GA, 3β-hydroxy-11-oxo-olean-12-ene-30-oic acid), the aglycone of glycyrrhizic acid isolated from licorice root, has been shown to have antitumor effects [1, 2] . To improve its antitumor activities, some structural modifications were previously done. We found that introduction
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of an alkoxyimino group at position C-3 along with a free C-30 carboxyl group improved the antiproliferative effects of GA [3] . We and other groups have also found that introduction of a 2-cyano-1-en-3-one on the A-ring, modification of ring C by converting the 11-oxo-12-ene to 12-oxo-9(11)-en and/or methyl esterification of the C-30 carboxylic group, significantly improved the cytotoxic activities of GA [4] [5] [6] . Similar structural modifications have been performed in oleanolic acid and it was found that 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO) and its methyl ester CDDO-Me were potent cytotoxic agents against tumor cells [7] [8] [9] .
To determine the importance of introducing a cyano-enone at the A-ring and methyl esterification at C30, glycyrrhetinic acid derivatives containing a nitrogen heterocycle at C-30 and with some additional modifications of the A-ring were designed and synthesized. The antiproliferative abilities of these compounds were tested in human HL-60 leukemia cells and compared with that of GA, methyl 2-cyano-3,11-dioxo-oleana-1,12-dien-30-oate (CDODO-Me-11) and methyl-2-cyano-3,12-dioxooleana-1,9(11)-dien-30-oate (CDODO-Me-12), which have been found to be potent antileukemia agents [4] . The synthesis of these compounds and their abilities to inhibit growth of HL-60 cells are presented in this communication.
Results and Discussion

Chemistry
Four groups of GA derivatives with a different A-ring structure and a replacement at the C-30 carboxylic group with a nitrogen heterocycle -piperidine, 4-piperidyl piperidine, 4-methyl piperazine, or piperazine -were synthesized starting from GA (Scheme 1). Compounds 1-3 were obtained using a routine method [5, 9, 10] . A benzyl group instead of a methyl group was used to protect the C-30 carboxylic acid as halogenolysis of the methyl ester with LiI in DMF gave an 11-oxo-13(18)-en by-product in approximately 20% yield [8] .
The benzyl group of compound 3 was removed under mild conditions to give the key intermediate 4 in 76% yield, which was used as the precursor for generating the 2-hydroxymethylene-3-keto compounds 5a-5c and the isoxazole 6. Addition of oxalyl chloride to compound 4 in chloroform gave the corresponding acyl chloride. Amides 5a-5c were prepared in 50%-72% yield by condensation between the acyl chloride and the corresponding nitrogen heterocycle.
Using the same procedures employed for obtaining compounds 5a-5c, the isoxazole amides 7a-7d were obtained from isoxazole 6, which was prepared in 85% yield by refluxing compound 4 with hydroxylamine hydrochloride in glacial acetic acid. Under basic conditions compounds 7a-7d were isomerized to the corresponding 2-cyano-3-keto compounds 8a-8d, that were then dehydrogenated using dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) in toluene to give the cyanoenone amides 9a-9d in fair to moderate yields. 
HL-60 cell growth inhibition activity
The abilities of compounds 5a-5c, 7a-7d, 8a-8d and 9a-9d to inhibit growth of HL-60 cells were determined and compared to that of GA, CDODO-Me-11 and CDODO-Me-12 ( Table 1 ). All of these new synthetic compounds had GI 50 values in the 0.5-20 μM range, which were much lower than that of GA (>40 μM). The activity order among these compounds was cyano-enone amides 9 > 2-hydroxymethylene-3-keto compounds 5 > isoxazoles 7 and 2-cyano-3-keto compounds 8. Since compounds 8a-8d have decreased activities comparing to that of compounds 9a-9d, it suggests that a double bond between C-1 and C-2 is required for maintaining high activity in these cyano-enone amides. Compounds 9a, 9c and 9d have activities similar to that of CDODO-Me-11. The antiproliferative activity of N-(2-cyano-3,11-dioxoolean-1,12-dien-30-yl)-4-piperidyl piperidine (9b) is two-fold more than that of CDODO-Me-11, indicating that the methyl ester could be replaced to further improve the antiproliferative activities of these compounds. Although 9b has lower activity than that of CDODO-Me-12, which has a 12-oxo-9(11)-en structure in the C-ring, the simple synthesis of 9b compared to that of CDODO-Me-12 makes this compound potentially more useful. The antitumor effects of compound 9b in additional cell lines are worthy of further study. 
Experimental
General
GA (purity over 98%) was purchased from Shanghai Haokang Chemicals Co. Ltd., China. Other reagents were bought from commercial suppliers in analytic grade and used without further purification, unless noted otherwise.
1 H-NMR and 13 C-NMR spectra were recorded on a Bruker ARX-300 instrument with tetramethylsilane as an internal standard. Infra-red (IR) spectra were recorded on a Bruker IR-27G spectrometer. Mass spectra (MS) were determined on a Finnigan MAT/USA spectrometer (LC-MS). HRMS spectra were obtained on a Bruker micrOTOF-Q in an ESI mode. The melting points were determined on an electrically heated X4 digital visual melting point apparatus and are uncorrected. TLC plates (Alugram silica gel G/UV254) were purchased from Macherey-Nagel GmbH & Co.
3,11-Dioxoolean-12-en-30-oic acid (1) . Jones' reagent (15 mL) was added to a solution of GA (10.0 g, 21.2 mmol) in THF (35 mL). The solution was stirred at 0 ºC for 1 h and then was poured into H 2 O (100 mL).
The precipitate was filtered and dried to afford compound 2 (9.5 g, 95.6% yield) as a white solid. (2) . BnBr (1.29 mL, 10.9 mmol) was added to a solution of 1 (5.0 g, 10.7 mmol) in DMF (50 mL). The mixture was stirred at 100 ºC for 3 h, cooled to room temperature and then poured into water (100 mL). The precipitate was filtered, washed with water to pH 7 and dried to give 2 (4.8 g, 80.9% yield) as a white solid. Benzyl 2-hydroxymethylene-3,11-dioxoolean-12-en-30-oate (3). NaH (3.84 g, 160 mmol) was added slowly to a solution of 2 (5.6 g, 10.1 mmol) in ethyl formate (100 mL). The mixture was stirred at r.t. for 10 min and methanol was added until no bubbles were generated. The mixture was diluted with a mixture of CH 2 Cl 2 and Et 2 O (1:2) and washed three times with 5% aqueous HCl solution. The organic layer was evaporated in vacuum and purified on a silica gel column with cyclohexane-acetone (v/v) = 20:1 to give 3 (4.7 g, 80.0% yield) as a white solid. 
Benzyl 3,11-dioxoolean-12-en-30-oate
2-Hydroxymethylene-3,11-dioxoolean-12-en-30-oic acid (4)
. 10% Pd/C (0.14 g) was added to a solution of 3 (0.76 g, 1.3 mmol) in THF (20 mL). The mixture was stirred at r. 
General procedure for the preparation of 2-hydroxymethylene-30-amides 5a-5c
To a solution of 4 (2.34 g, 4 mmol) in chloroform (10 mL), oxalyl chloride (2 mL) was added. The mixture was stirred at r.t. for 1 hr and excess oxalyl chloride was removed by co-evaporation with hexane (three times). The obtained solid was dissolved in chloroform (30 mL) and an appropriate nitrogen heterocycle (6 mmol) was added. The mixture was stirred at r.t. for 5 min and washed three times with 5% aqueous HCl solution. The organic layer was dried over anhydrous MgSO 4 . After MgSO 4 was removed by filtration, the filtrate was concentrated in vacuum and the residue was purified on a silica gel column with chloroform-methanol (v/v) = 50:1 to give a white solid. The Rf values were determined using TLC plates with chloroform-methanol (v/v) = 10:1. Hydroxymethylene-3,11-dioxoolean-12-en-30-yl)-piperidine (5a) . Crystallization of the white solid from hexane and acetone (10:1) afforded white needles (1.6 g, 2.9 mmol). Yield: 72%; R f = 0. HCl (0.36 g, 5.1 mol), and anhydrous sodium acetate (0.04 g, 0.49 mmol) were refluxed for 1.5 h in acetic acid (20 mL), cooled, and poured into ice-water. The precipitate was filtered, dried, and purified on a silica gel column with petroleum ether-acetone (v/v) = 20:1 to give 6 (0.74 g, 85.0% yield) as a white solid. 1 
N-(2-
N-(2-Hydroxymethylene-3,11-dioxoolean-12-en-30-yl)-4-piperidyl piperidine (5b
General procedure for the preparation of isoxazolo[4,5-b]olean-11-oxo-12-en-30-amides 7a-7d
Oxalyl chloride (2 mL) was added to a solution of 6 (0.98 g, 2 mmol) in chloroform (10 mL). The mixture was stirred at r.t. for 1 hr and excess oxalyl chloride was removed by evaporation with hexane (three times). The obtained solid was dissolved in 30 mL chloroform and a nitrogen heterocycle (6 mmol) was added. The mixture was stirred at r.t. for 5 min and concentrated under vacuum. The residue was purified on a silica gel column with chloroform-methanol (v/v) = 50:1 to give a white solid. The Rf values were determined by TLC plates with chloroform-methanol (v/v) = 10:1. 
N-(Isoxazolo[4,5-b]olean-11-oxo-12-en-30-yl)-piperidine (7a
N-(Isoxazolo[4,5-b]olean-11-oxo-12-en-30-yl)-4-piperidyl piperidine (7b
N-(Isoxazolo[4,5-b]olean-11-oxo -12-en-30-yl)-4-methyl piperazine (7c
General procedure for the preparation of 2-cyano-3,11-dioxoolean-12-en-30-amides 8a-8d
NaOCH 3 (7.25 g, 134 mmol) was added to a solution of isoxazolo[4,5-b]-olean-11-oxo-12-en-30-amide (3.9 mmol) in MeOH (60 mL) and Et 2 O (125 mL). The mixture was stirred at r.t. for 8 hr and was extracted with a mixture of CH 2 Cl 2 and Et 2 O (1:2). The extract was washed three times with 5% aqueous HCl solution and the acidic washings were re-extracted with a mixture of CH 2 Cl 2 and Et 2 O (1:2). The combined organic layers were evaporated in vacuum and the precipitate was purified on a silica gel column with chloroform-methanol (v/v) = 50:1 to give a white solid. The Rf values were determined by TLC plates with chloroform-methanol (v/v) = 10:1. Cyano-3,11-dioxoolean-12-en-30-yl)-piperridine (8a) . Crystallization of the white solid from hexane and EtOAc ( 
N-(2-
N-(2-Cyano-3,11-dioxoolean-12-en-30-yl)-4-methyl piperazine (8c
General procedure for the preparation of 2-cyano-3,11-dioxoolean-1,12-dien-30-amide derivatives 9a-9d
A mixture of 2-cyano-3,11-dioxoolean-12-en-30-amide derivative (3 mmol) and DDQ (98%) (0.77 g, 3.32 mmol) in dry toluene (80 mL) was heated under 80 ºC for 30 min. After insoluble material was removed by filtration, the filtrate was evaporated under vacuum to give a brown solid. The solid was purified on a silica gel column with chloroform-methanol (v/v) = 50:1. The R f values were determined by TLC plates with chloroform-methanol (v/v) = 10:1. Cyano-3,11-dioxoolean-1,12-dien-30-yl) 
N-(2-
Cell culture
HL-60 cells were cultured in RPMI 1640. The media were supplemented with 100 units/mL penicillin, 100 μg/mL streptomycin, 1 mmol/L L-glutamine, and 10% (v/v) heat-inactivated fetal bovine serum.
Cell growth inhibition assay
All compounds were dissolved in DMSO. A stock solution of 20 mmol/L of each compound was prepared in DMSO and stored in aliquots at -20 ºC. A working solution was diluted with ethanol and fresh medium before assaying. The final concentration of ethanol in the medium was less than 1% and the final concentration of DMSO was less than 0.1%. Cells were seeded at a density of 4 × 10 4 cells/mL in 24 well plates with various concentrations of the tested compounds and incubated for 3 days. Total cell number in each group was determined using a hemocytometer. The cell growth inhibitory ability was expressed as the ratio of the cell number in the groups treated with the compounds to that of cells treated with DMSO and/or ethanol. The concentration (GI 50 ) which inhibited half of cell growth was calculated.
Conclusions
Fifteen novel glycyrrhetinic acid derivatives containing a nitrogen heterocycle at C-30 and with different substituents on the A-ring were designed and synthesized. The antiproliferative effects of these compounds were determined in HL-60 cells. The results reveal that: 1) introduction of the cyano-enone moiety into the A-ring of GA significantly improves the antiproliferative activities in leukemia cells and 2) N-(2-cyano-3,11-dioxoolean-1,12-dien-30-yl)-4-piperidyl piperidine (9b) is the most active compound among these novel GA derivatives with a 11-oxo-12-en structure.
